Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-07

AUTHORS

L. S. Johnson, D. Patel, E. A. King, J. N. Maslow

ABSTRACT

Cascade reporting (CR) involves reporting the susceptibilities of broad-spectrum agents only when the organism is resistant to more narrow-spectrum agents. The purpose of this study is to evaluate the impact of CR on antibiotic de-escalation practices and to characterize the impact of CR on clinical outcomes. CR rules were implemented in the microbiology laboratory at Atlantic Health System (AHS) in June 2013. A retrospective chart review was conducted at two community teaching hospitals in adult patients who had a blood culture positive for a Gram-negative organism susceptible to cefazolin and who were empirically treated with broad-spectrum beta-lactam (BSBL) antibiotics. De-escalation practices were compared in the pre-CR (July 2012-December 2012) and post-CR (July 2013-December 2013) periods. The primary endpoint was the percentage of patients whose BSBL agent was de-escalated to agents listed on the post-CR antibiotic susceptibility report within 48 h of the final report. Secondary endpoints include the difference in pre-CR and post-CR periods in terms of hospital length of stay, in-hospital mortality, 30-day readmission, Clostridium difficile infections, and re-initiation of a BSBL agent within 7 days. A total of 73 patients were included; 31 in the pre-CR and 42 in the post-CR period. Patients had similar baseline characteristics. Therapy was de-escalated in 48 % of pre-CR vs 71 % of post-CR patients (p = 0.043). No significant differences were observed in secondary endpoints between patients in the pre-CR and post-CR periods. CR resulted in significant improvements in de-escalation practices without affecting safety outcomes. More... »

PAGES

1151-1157

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10096-016-2645-5

DOI

http://dx.doi.org/10.1007/s10096-016-2645-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1009201781

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27130036


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacteremia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cefazolin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Comorbidity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Bacterial", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Negative Bacteria", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gram-Negative Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intensive Care Units", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Microbial Sensitivity Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Outcome Assessment (Health Care)", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Department of Pharmacy, CHI Memorial, 2525 DeSales Avenue, 37404, Chattanooga, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "L. S.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Morristown Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.416113.0", 
          "name": [
            "Department of Pharmacy, Morristown Medical Center, 100 Madison Avenue, 07960, Morristown, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Patel", 
        "givenName": "D.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Overlook Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.417328.b", 
          "name": [
            "Department of Pharmacy, Overlook Medical Center, 99 Beauvoir Avenue, 07901, Summit, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "King", 
        "givenName": "E. A.", 
        "id": "sg:person.01366306563.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366306563.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Morristown Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.416113.0", 
          "name": [
            "Division of Infectious Diseases, Department of Medicine, Morristown Medical Center, 100 Madison Avenue, 07960, Morristown, NJ, USA", 
            "GeneOne Life Science, Inc., 1040 DeKalb Pike, Suite 200, 19422, Blue Bell, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maslow", 
        "givenName": "J. N.", 
        "id": "sg:person.0757111557.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757111557.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00134-013-3077-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003257648", 
          "https://doi.org/10.1007/s00134-013-3077-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10096-012-1786-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004083483", 
          "https://doi.org/10.1007/s10096-012-1786-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10096-012-1786-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004083483", 
          "https://doi.org/10.1007/s10096-012-1786-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/45.5.705", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004305978"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkg032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005283385"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jiph.2014.09.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006280595"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/595011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012478118"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/dkr088", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020211655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1086/510393", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047721791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jac/40.4.595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052788774"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079383788", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/46.9.1816", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079383788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/46.9.1816", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079383788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/46.9.1816", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079383788"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-07", 
    "datePublishedReg": "2016-07-01", 
    "description": "Cascade reporting (CR) involves reporting the susceptibilities of broad-spectrum agents only when the organism is resistant to more narrow-spectrum agents. The purpose of this study is to evaluate the impact of CR on antibiotic de-escalation practices and to characterize the impact of CR on clinical outcomes. CR rules were implemented in the microbiology laboratory at Atlantic Health System (AHS)\u00a0in June 2013. A retrospective chart review was conducted at two community teaching hospitals in adult patients who had a blood culture positive for a Gram-negative organism susceptible to cefazolin and who were empirically treated with broad-spectrum beta-lactam (BSBL) antibiotics. De-escalation practices were compared in the pre-CR (July 2012-December 2012) and post-CR (July 2013-December 2013) periods. The primary endpoint was the percentage of patients whose BSBL agent was de-escalated to agents listed on the post-CR antibiotic susceptibility report within 48\u00a0h of the final report. Secondary endpoints include the difference in pre-CR and post-CR periods in terms of hospital length of stay, in-hospital mortality, 30-day readmission, Clostridium difficile infections, and re-initiation of a BSBL agent within 7\u00a0days. A total of 73 patients were included; 31 in the pre-CR and 42 in the post-CR period. Patients had similar baseline characteristics. Therapy was de-escalated in 48\u00a0% of pre-CR vs 71\u00a0% of post-CR patients (p\u2009=\u20090.043). No significant differences were observed in secondary endpoints between patients in the pre-CR and post-CR periods. CR resulted in significant improvements in de-escalation practices without affecting safety outcomes. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10096-016-2645-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093599", 
        "issn": [
          "0934-9723", 
          "1435-4373"
        ], 
        "name": "European Journal of Clinical Microbiology & Infectious Diseases", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia", 
    "pagination": "1151-1157", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2bd5e19664f7da493e26081ed8dbbc5e67169d4dad679e3c991b06d17df95cfe"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27130036"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8804297"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10096-016-2645-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1009201781"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10096-016-2645-5", 
      "https://app.dimensions.ai/details/publication/pub.1009201781"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8663_00000480.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10096-016-2645-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10096-016-2645-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10096-016-2645-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10096-016-2645-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10096-016-2645-5'


 

This table displays all metadata directly associated to this object as RDF triples.

205 TRIPLES      21 PREDICATES      59 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10096-016-2645-5 schema:about N037a88e384e342ea97fd780c3277624d
2 N1a712106c7e14209941b7528aa05e5b2
3 N1d3566d25b4a47339efdb70cae7aae71
4 N28a8263868b6457996f2c793d0c62d2c
5 N33203b625d9e4a4ab3122b208fb80c9a
6 N3c05ff4833cb487f94210c8cba5c5ed6
7 N52504073dda848098efaa7b74314ba28
8 N5557dcd80f1043adbb1caf4510499199
9 N5917f69eaccb4e54b5ef1307a8356da1
10 N6948333308a34bf582b8f1101fdfe349
11 N892907116da041c49984ff37e3cb6df9
12 N8e92a16e5b3846dbba49245f0d4ce725
13 N9f9834b84b6d48d99a452b82eae32d2e
14 Nb74451890904498f817a471f63639608
15 Nc6e5ec7091e1461f86cf46fdbd7c38d2
16 Ncc757a39e846436da2b54daaeea0ea26
17 Nd040d2086b864738bd54382b0397c347
18 Ne8a6c605453642019e54ddd81fa42407
19 Nf51e8bffecf14f1fa2c0c07572f3f023
20 anzsrc-for:11
21 anzsrc-for:1117
22 schema:author N9a90c60f6dc54055ad6dcd9a08cf954d
23 schema:citation sg:pub.10.1007/s00134-013-3077-7
24 sg:pub.10.1007/s10096-012-1786-4
25 https://app.dimensions.ai/details/publication/pub.1079383788
26 https://doi.org/10.1016/j.jiph.2014.09.004
27 https://doi.org/10.1086/510393
28 https://doi.org/10.1086/595011
29 https://doi.org/10.1093/ajhp/46.9.1816
30 https://doi.org/10.1093/jac/40.4.595
31 https://doi.org/10.1093/jac/45.5.705
32 https://doi.org/10.1093/jac/dkg032
33 https://doi.org/10.1093/jac/dkr088
34 schema:datePublished 2016-07
35 schema:datePublishedReg 2016-07-01
36 schema:description Cascade reporting (CR) involves reporting the susceptibilities of broad-spectrum agents only when the organism is resistant to more narrow-spectrum agents. The purpose of this study is to evaluate the impact of CR on antibiotic de-escalation practices and to characterize the impact of CR on clinical outcomes. CR rules were implemented in the microbiology laboratory at Atlantic Health System (AHS) in June 2013. A retrospective chart review was conducted at two community teaching hospitals in adult patients who had a blood culture positive for a Gram-negative organism susceptible to cefazolin and who were empirically treated with broad-spectrum beta-lactam (BSBL) antibiotics. De-escalation practices were compared in the pre-CR (July 2012-December 2012) and post-CR (July 2013-December 2013) periods. The primary endpoint was the percentage of patients whose BSBL agent was de-escalated to agents listed on the post-CR antibiotic susceptibility report within 48 h of the final report. Secondary endpoints include the difference in pre-CR and post-CR periods in terms of hospital length of stay, in-hospital mortality, 30-day readmission, Clostridium difficile infections, and re-initiation of a BSBL agent within 7 days. A total of 73 patients were included; 31 in the pre-CR and 42 in the post-CR period. Patients had similar baseline characteristics. Therapy was de-escalated in 48 % of pre-CR vs 71 % of post-CR patients (p = 0.043). No significant differences were observed in secondary endpoints between patients in the pre-CR and post-CR periods. CR resulted in significant improvements in de-escalation practices without affecting safety outcomes.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N3d77441a7e034dee87f485ecc1b18553
41 N5c5f3eccf37f463d8c92c4df72e071bc
42 sg:journal.1093599
43 schema:name Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia
44 schema:pagination 1151-1157
45 schema:productId N04764ef1fc7f41cfaa8f09aada565b9d
46 N29b90232e7f74d2fb57c1d7df3225ec5
47 N9dcaec574fe349d79409ae92beab40d5
48 Nb8bdfccd3de44bc19140b43c0f76d273
49 Ncec759cf582142409a28d6611c0f2545
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009201781
51 https://doi.org/10.1007/s10096-016-2645-5
52 schema:sdDatePublished 2019-04-10T14:52
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N58d1ba0211324aef8c04d6e8f92a38c7
55 schema:url http://link.springer.com/10.1007/s10096-016-2645-5
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N037a88e384e342ea97fd780c3277624d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Intensive Care Units
61 rdf:type schema:DefinedTerm
62 N04764ef1fc7f41cfaa8f09aada565b9d schema:name dimensions_id
63 schema:value pub.1009201781
64 rdf:type schema:PropertyValue
65 N1a712106c7e14209941b7528aa05e5b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Retrospective Studies
67 rdf:type schema:DefinedTerm
68 N1d3566d25b4a47339efdb70cae7aae71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Adult
70 rdf:type schema:DefinedTerm
71 N28a8263868b6457996f2c793d0c62d2c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Anti-Bacterial Agents
73 rdf:type schema:DefinedTerm
74 N29b90232e7f74d2fb57c1d7df3225ec5 schema:name pubmed_id
75 schema:value 27130036
76 rdf:type schema:PropertyValue
77 N33203b625d9e4a4ab3122b208fb80c9a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Comorbidity
79 rdf:type schema:DefinedTerm
80 N3baa967ca58b4759aa04e33eb2c048bc rdf:first sg:person.0757111557.11
81 rdf:rest rdf:nil
82 N3c05ff4833cb487f94210c8cba5c5ed6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Gram-Negative Bacteria
84 rdf:type schema:DefinedTerm
85 N3d77441a7e034dee87f485ecc1b18553 schema:issueNumber 7
86 rdf:type schema:PublicationIssue
87 N52504073dda848098efaa7b74314ba28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Aged
89 rdf:type schema:DefinedTerm
90 N5557dcd80f1043adbb1caf4510499199 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Gram-Negative Bacterial Infections
92 rdf:type schema:DefinedTerm
93 N58d1ba0211324aef8c04d6e8f92a38c7 schema:name Springer Nature - SN SciGraph project
94 rdf:type schema:Organization
95 N5917f69eaccb4e54b5ef1307a8356da1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Drug Resistance, Bacterial
97 rdf:type schema:DefinedTerm
98 N5c5f3eccf37f463d8c92c4df72e071bc schema:volumeNumber 35
99 rdf:type schema:PublicationVolume
100 N6948333308a34bf582b8f1101fdfe349 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Male
102 rdf:type schema:DefinedTerm
103 N755453f06e48457da297eb0c4c7fab4a rdf:first sg:person.01366306563.29
104 rdf:rest N3baa967ca58b4759aa04e33eb2c048bc
105 N892907116da041c49984ff37e3cb6df9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Cefazolin
107 rdf:type schema:DefinedTerm
108 N8e92a16e5b3846dbba49245f0d4ce725 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Microbial Sensitivity Tests
110 rdf:type schema:DefinedTerm
111 N9a90c60f6dc54055ad6dcd9a08cf954d rdf:first Nd0d688c04c4446cba39045fe4ca187ff
112 rdf:rest Nd1e067c78c9d4a5ca3cf47dd640a3f39
113 N9dcaec574fe349d79409ae92beab40d5 schema:name readcube_id
114 schema:value 2bd5e19664f7da493e26081ed8dbbc5e67169d4dad679e3c991b06d17df95cfe
115 rdf:type schema:PropertyValue
116 N9f9834b84b6d48d99a452b82eae32d2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Outcome Assessment (Health Care)
118 rdf:type schema:DefinedTerm
119 Na928e3719aa8454db51cb95d2d03022f schema:name Department of Pharmacy, CHI Memorial, 2525 DeSales Avenue, 37404, Chattanooga, TN, USA
120 rdf:type schema:Organization
121 Nb74451890904498f817a471f63639608 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Middle Aged
123 rdf:type schema:DefinedTerm
124 Nb8bdfccd3de44bc19140b43c0f76d273 schema:name doi
125 schema:value 10.1007/s10096-016-2645-5
126 rdf:type schema:PropertyValue
127 Nc6e5ec7091e1461f86cf46fdbd7c38d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Bacteremia
129 rdf:type schema:DefinedTerm
130 Ncc757a39e846436da2b54daaeea0ea26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Risk Factors
132 rdf:type schema:DefinedTerm
133 Ncec759cf582142409a28d6611c0f2545 schema:name nlm_unique_id
134 schema:value 8804297
135 rdf:type schema:PropertyValue
136 Nd040d2086b864738bd54382b0397c347 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Aged, 80 and over
138 rdf:type schema:DefinedTerm
139 Nd0d688c04c4446cba39045fe4ca187ff schema:affiliation Na928e3719aa8454db51cb95d2d03022f
140 schema:familyName Johnson
141 schema:givenName L. S.
142 rdf:type schema:Person
143 Nd1e067c78c9d4a5ca3cf47dd640a3f39 rdf:first Nde68df052e1d4fb3a99702b917819891
144 rdf:rest N755453f06e48457da297eb0c4c7fab4a
145 Nde68df052e1d4fb3a99702b917819891 schema:affiliation https://www.grid.ac/institutes/grid.416113.0
146 schema:familyName Patel
147 schema:givenName D.
148 rdf:type schema:Person
149 Ne8a6c605453642019e54ddd81fa42407 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Female
151 rdf:type schema:DefinedTerm
152 Nf51e8bffecf14f1fa2c0c07572f3f023 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Humans
154 rdf:type schema:DefinedTerm
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
159 schema:name Public Health and Health Services
160 rdf:type schema:DefinedTerm
161 sg:journal.1093599 schema:issn 0934-9723
162 1435-4373
163 schema:name European Journal of Clinical Microbiology & Infectious Diseases
164 rdf:type schema:Periodical
165 sg:person.01366306563.29 schema:affiliation https://www.grid.ac/institutes/grid.417328.b
166 schema:familyName King
167 schema:givenName E. A.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366306563.29
169 rdf:type schema:Person
170 sg:person.0757111557.11 schema:affiliation https://www.grid.ac/institutes/grid.416113.0
171 schema:familyName Maslow
172 schema:givenName J. N.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0757111557.11
174 rdf:type schema:Person
175 sg:pub.10.1007/s00134-013-3077-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003257648
176 https://doi.org/10.1007/s00134-013-3077-7
177 rdf:type schema:CreativeWork
178 sg:pub.10.1007/s10096-012-1786-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004083483
179 https://doi.org/10.1007/s10096-012-1786-4
180 rdf:type schema:CreativeWork
181 https://app.dimensions.ai/details/publication/pub.1079383788 schema:CreativeWork
182 https://doi.org/10.1016/j.jiph.2014.09.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006280595
183 rdf:type schema:CreativeWork
184 https://doi.org/10.1086/510393 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047721791
185 rdf:type schema:CreativeWork
186 https://doi.org/10.1086/595011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012478118
187 rdf:type schema:CreativeWork
188 https://doi.org/10.1093/ajhp/46.9.1816 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079383788
189 rdf:type schema:CreativeWork
190 https://doi.org/10.1093/jac/40.4.595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052788774
191 rdf:type schema:CreativeWork
192 https://doi.org/10.1093/jac/45.5.705 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004305978
193 rdf:type schema:CreativeWork
194 https://doi.org/10.1093/jac/dkg032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005283385
195 rdf:type schema:CreativeWork
196 https://doi.org/10.1093/jac/dkr088 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020211655
197 rdf:type schema:CreativeWork
198 https://www.grid.ac/institutes/grid.416113.0 schema:alternateName Morristown Medical Center
199 schema:name Department of Pharmacy, Morristown Medical Center, 100 Madison Avenue, 07960, Morristown, NJ, USA
200 Division of Infectious Diseases, Department of Medicine, Morristown Medical Center, 100 Madison Avenue, 07960, Morristown, NJ, USA
201 GeneOne Life Science, Inc., 1040 DeKalb Pike, Suite 200, 19422, Blue Bell, PA, USA
202 rdf:type schema:Organization
203 https://www.grid.ac/institutes/grid.417328.b schema:alternateName Overlook Medical Center
204 schema:name Department of Pharmacy, Overlook Medical Center, 99 Beauvoir Avenue, 07901, Summit, NJ, USA
205 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...